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Background: Adherence to cardiac medication regimes is essential for effective treatment of 8 
cardiovascular disease but is unsatisfactory in Australia and little studied in Iraq. 9 
Aim: This study evaluated and compared adherence to cardiac medications and potentially predictive 10 
factors based on the Theory of Planned Behaviour (TPB) in patients with cardiovascular disease 11 
admitted to hospital and attending cardiac services in Australia and Iraq. 12 
Methods: A cross-sectional multi-centre comparative study involving 246 cardiac patients was 13 
conducted in Australia (one hospital in Sydney) and Iraq (three cardiac hospitals in Baghdad) between 14 
October 2016 and December 2017. Adherence to medications and related factors were examined using 15 
established, validated questionnaires, formally translated and validated into Arabic for Iraqi 16 
participants. Binary logistic regression was conducted to determine those factors independently 17 
predictive of cardiac medication adherence, in Australia and Iraq. 18 
Findings: A significantly higher proportion (64.3%) of Iraqi than Australian (37.5%) cardiac patients 19 
reported medium/low levels of adherence to their cardiac medications. After adjusting for confounding 20 
factors, the ability to correctly self-administer and refill medications, and beliefs about cardio-protective 21 
medication were identified as independent predictors of cardiac medication adherence behaviour in both 22 
Australian and Iraqi participants. In Iraq, patients recruited from out-patient cardiac clinics were 23 
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significantly more likely to report adherent behaviours than patients recruited as in-patients of the 24 
cardiac ward. 25 
Conclusion: Non-adherence to cardiac medications differed but was sub-optimal in both Australian and 26 
Iraqi patient samples, in both countries, adherence was associated with patients’ beliefs about 27 
medications, and ability to self-administer and refill medications. Clinical nurses and pharmacists need 28 
to investigate these factors at every point in the cardiac trajectory to optimise medication adherence.  29 
Keywords: Cardiovascular disease, Australia, Iraq, cardiology, medication adherence, beliefs, 30 
medication refill, cardiac nursing, theory of planned behaviour. 31 
Summary of Relevance 32 
Problem 33 
Cardiovascular disease remains the major cause of mortality in developed and developing countries.  34 
What is already known: 35 
Cardiovascular medication adherence is suboptimal, increasing the risk of morbidity. Few medication 36 
adherence investigations have been conducted in Australia and none have been published from Iraq.  37 
What this paper adds:  38 
This is the first study to compare adherence to cardiac medications and factors potentially predictive of 39 
medication non-adherence in patients with cardiovascular disease in Australia and Iraq. Outcomes can 40 
support the development of nurse-led behavioural approaches to improve medication adherence in 41 
patients with cardiovascular disease. Findings flag the importance for nurses should focus on patients’ 42 
beliefs about their medication and their ability to self-administer and refill medications, taking into 43 





1. Introduction  47 
Cardiovascular disease (CVD) is the major cause of death in both developed and developing 48 
countries (Wirtz, Kaplan, Kwan, & Laing, 2016). CVD encompasses a variety of disease entities and 49 
specific symptom complexes, treated by a variety of approaches, pharmaceutical, surgical and 50 
interventional radiology. In developed countries, the annual mortality associated with CVD in 2013 was 51 
4 million people, with more than 1.4 million dying prematurely before the age of 75 years (Townsend 52 
et al., 2016). In Australia, CVD accounts for 18% of the total burden of disease and was responsible for 53 
43,963 deaths in 2016 and more than 490,000 hospital admissions in 2014-2015 (Heart Foundation, 54 
2016). According to the Australian Pharmaceutical Benefits Scheme (PBS), the total cost of CVD 55 
medications in 2015-16 was AU$1.448 billion for a total estimated population of 23.781.200 people 56 
(Australian Bureau of Statistics, 2015), comprising 20% of the total health expenditure (Australian 57 
Institute of Health and Welfare, 2017).  58 
Prevalence rates of CVD are increasing, and particularly in Middle Eastern countries such as 59 
Iraq, where CVD accounted for 27,500 deaths in 2012, 16.5% of all-cause mortality (World Health 60 
Organization, 2013). The Iraqi government subsidises the cost of a wide range of prescription 61 
medicines, including those for CVD. Government health expenditure was US$82.2 billion in 2010 with 62 
an estimated 39% spent on cardiovascular medications, totalling around US$32 billion for a population 63 
of 30.868.156 people (Al Hilfi, Lafta, & Burnham, 2013). The standard of treatment and care remains 64 
suboptimal in Iraq and the health care system is poorly effective in managing long-term disease such as 65 
CVD (Alwan, 2004). 66 
Long-term management of CVD is largely based on life-style modifications such as diet, 67 
physical exercises, smoking cessation and medications are usually required over sustained periods, 68 
often for life (Australian Institute of Health and Welfare, 2017). Hence, adherence to medication 69 
regimes and the ability to maintain treatment as prescribed is essential to managing symptoms, delaying 70 
or preventing disease progression, premature disability and death (World Health Organisation, 2003). 71 
Unless patients living with CVD are able to maintain treatments as prescribed, the resources committed 72 
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by the pharmaceutical industry and healthcare providers to drug development, diagnosis and 73 
prescription are wasted.  74 
2. Background 75 
Medication adherence is defined as the extent to which patients take medications as prescribed 76 
by their health care providers (World Health Organisation, 2003). Poor medication adherence is a key 77 
factor impeding disease control among those with CVD (World Health Organisation, 2003). Despite 78 
evidence of the effectiveness of cardiac medications such as anti-platelet agents, beta-blockers, 79 
angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), and 80 
aldosterone receptor antagonists (ARA) (Levy, Huang, Huang, & Michael Ho, 2018) to manage CVD 81 
symptoms, non-adherence rates range from 44.4% to 61% across settings and countries (Paradkar & 82 
Sinha, 2017). Studies report that adherence to cardio-protective medications is sub-optimal in both 83 
resource-limited and resource-rich countries (Chowdhury, Khan, & Heydon, 2013). This is a major 84 
problem internationally; as such, there may be lessons to learn from multi-national comparisons, 85 
studying the problem in different settings and contexts. 86 
Long-term cardiac medication adherence by Australian patients with CVD  is unsatisfactory, 87 
with non-adherence rates ranging between 14% and 43% from 2010 to 2014 (McKenzie, McLaughlin, 88 
Clark, & Doi, 2015). To date, few investigations of medication adherence have been conducted with 89 
Australian patients with chronic conditions, especially patients with CVD, and no published studies 90 
report adherence to cardiovascular medications in Iraq. Many medication adherence studies have been 91 
conducted in developed countries, but it is difficult to extrapolate the results of these studies to 92 
developing countries such as Iraq due to disparities in healthcare systems, social and cultural factors 93 
that affect health beliefs and practice (Sharrad, Hassali, & Shafie, 2009). Medication non-adherence is 94 
a complex and multi-faceted problem, influenced by a wide range of sociodemographic and economic 95 
characteristics, behavioural and cognitive problems, medication complexity and social support systems 96 
(Marshall, Wolfe, & McKevitt, 2012). Cultural differences among patients from diverse national 97 
backgrounds, racial and ethnic groups may contribute to disparities of cardiovascular medication 98 
adherence (Traylor, Schmittdiel, Uratsu, Mangione, & Subramanian, 2010). Cultural differences can 99 
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negatively influence patients’ beliefs about medication and their perceptions of treatment, and 100 
difference in generation, household composition and religion may also create variability in beliefs and 101 
behaviours (Horne et al., 2004). Multiple different factors may, therefore, contribute to medication non-102 
adherence in developed and developing countries (Cooney et al., 2009).  103 
In patients with CVD, negative perceptions of medications (Choudhry et al., 2011), beliefs 104 
about benefits and harms of medications (Horne et al., 2013), low levels of social support (Park, Howie-105 
Esquivel, Whooley, & Dracup, 2015), low self-efficacy (Greer, Milner, Marcello, & Mazin, 2015), poor 106 
medication self-management, attitudes and sociocultural norms (Martin, Williams, Haskard, & 107 
DiMatteo, 2005) and problems refilling medications have all been found to influence adherence to 108 
cardiac medications (Kripalani, Risser, Gatti, & Jacobson, 2009). Other contributing factors include the 109 
complexity of treatment, patients’ forgetfulness (Karakurt & Kaşikçi, 2012), the presence of 110 
comorbidities (Al Qasem, Smith, & Clifford, 2011) and medication side effects (Molloy & O’Carroll, 111 
2017).  112 
At an individual level, the engagement of individuals in health-related behaviours, such as 113 
medication adherence, may be explained by applying behavioural theories. This study used Ajzen 114 
(1991) Theory of Planned Behaviour (TBP) to identify factors predictive of medication adherence in 115 
patients with CVD (Figure 1). The TBP encompasses attitudes (e.g. positive or negative beliefs about 116 
the behaviour), subjective norms (e.g. the degree to which social consensus values and role models 117 
reinforce behaviours; perceived social support to perform the behaviour), and perceived behavioural 118 
control (e.g. perceptions of self-efficacy to perform the behaviour) (Table 1). The theory explains how 119 
these factors might impact patients’ intentions or directly influence their behaviours such as adherence 120 
to cardiac medications (Armitage & Conner, 2001).  121 
The social and cultural contexts of Australia and Iraq differ, as developed and developing 122 
nations of the West and the Middle East. However, both have high prevalence rates of CVD, and for 123 
both it is crucial to understand adherence to CVD medications and factors which predict this. Cross-124 
national comparisons might offer information, for example cultural insights, not available with a single 125 
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country study. The aim of this study, therefore, was to explore medication adherence behaviours of 126 
patients with CVD, admitted to hospital and attending out-patient services, in Australia and Iraq and to 127 
determine factors predictive of adherence to cardiac medications regimes. Findings could inform 128 
development of preventive strategies to improve medication adherence internationally through tailored 129 
nurse-led adherence interventions utilising reliable adherence assessment tools and the most effective 130 
and appropriate adherence approaches. 131 
3. Methods 132 
3.1 Aims and objectives 133 
The aim of this study was to evaluate and compare adherence to cardiac medications and factors 134 
potentially predictive of this in patients with CVD in Australia and Iraq. 135 
Objectives were to: 136 
1) Identify and compare the levels of cardiac medication adherence in patients with CVD in Australia 137 
and Iraq.  138 
2) Examine and compare socio demographic, health related, attitudinal and behavioural factors 139 
potentially predictive of medication adherence in these countries using the lens of the Theory of Planned 140 
Behaviour (TPB) (Ajzen, 1991).  141 
3.2 Design 142 
This was a cross-sectional multi-centre comparative study conducted in Australia (one hospital 143 
in Sydney) and Iraq (three cardiac hospitals in Baghdad). Survey design was used to explore cardiac 144 
patients’ medication adherence. 145 
3.3 Study settings 146 
In Australia, participants were recruited from the in-patient cardiology ward and out-patient 147 
cardiac rehabilitation centre of an acute tertiary hospital in Sydney. This hospital has inpatient 148 
diagnostic and interventional cardiac services including a cardiothoracic intensive care and sub-acute 149 
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surgical ward, a coronary care unit and sub-acute cardiology ward. The out-patient cardiac rehabilitation 150 
service screened in-patients and external referrals for delivery of cardiac rehabilitation programs 151 
including structured, supervised group exercise and information sessions, and referral to relevant 152 
services. 153 
In Iraq patients were recruited at three cardiac hospitals in Baghdad, Iraq. These were major 154 
tertiary teaching hospitals offering a range of cardiac services including cardiac out-patient clinics and 155 
in-patient cardiac services for approximately 570 beds with intensive and coronary care units, 156 
cardiology and cardiac surgery departments. These three public hospitals are operated by the Iraqi 157 
Ministry of Health, which provides cardiac services for people referred nation-wide, including cardiac 158 
emergency and critical care cases. At the time of this study, most Iraqi hospitals were struggling to 159 
recover from years of war, shortages in health facilities and the health workforce, with inadequately 160 
trained healthcare professionals and poor health-care finance (The Iraqi Ministry of Health, 2012).  161 
3.4 Participants, sampling and sample size 162 
Participants were patients who had been admitted to hospital for an acute cardiac event or 163 
referred to and attended a cardiac rehabilitation program or out-patient cardiac clinic between October 164 
2016 and December 2017. Similar inclusion criteria were applied in both countries: 18 years of age or 165 
older; diagnosed with cardiac disease; currently taking at least one cardio-protective medication and 166 
having primary responsibility for taking their own medication before admission to hospital or when 167 
attending cardiac rehabilitation. Participants were required to be able to read, speak and understand 168 
English (in Australia) or Arabic (in Iraq). Patients who were blind, deaf or medically deemed unable to 169 
provide consent were excluded. Patients in the cardiac ward were excluded if they were newly 170 
diagnosed with no previous history of cardiovascular disease and hence no prior history of taking 171 
prescribed cardiac medication.     172 
Recruitment occurred under the supervision of the clinical nurse consultant for cardiac 173 
rehabilitation and the clinical pharmacist for the cardiac ward in Australia and the clinical nurse 174 
specialist for all sites in Iraq, with the agreement of the directors of nursing and the cardiology 175 
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consultants of both sites. Patients were screened using the study inclusion/exclusion criteria by the 176 
clinical nurse consultant/specialist and the clinical pharmacist. Eligible members of consecutive cohorts 177 
of patients who expressed interest in the project were referred to the researcher. In Australia, approvals 178 
to conduct this study were granted by the appropriate health district and university Human Research 179 
Ethics Committees in June 2016 (references: 16/085 (16/085 -HREC/16/POWH/218; ETH16-0635), 180 
and the health district Human Research Ethics Committees from the three hospitals in Iraq approved 181 
the study in June 2017. Participants’ privacy and confidentiality was maintained at all times and 182 
informed consent obtained from all participants. 183 
3.5 Sample size determination 184 
A sample size of 120 participants in each country was calculated to demonstrate a moderate 185 
sized effect (α = 0.05, 5% level of significant) and power = 0.80 (Ma, Zhou, Zhou, & Huang, 2014). 186 
We anticipated approximately 50% of eligible patients might participate.  187 
3.6 Data collection procedures 188 
In order to assess medication adherence and associated factors, a valid, reliable and culturally 189 
acceptable instrument is required. Data collection procedures at both sites were performed under the 190 
same methods and conditions using the same instruments for the respective language after formal 191 
translation procedures had been performed in Iraq.  192 
In both Australia and Iraq, data collection took place during patients’ stay in the inpatient 193 
cardiac ward, during attendance at cardiac rehabilitation sessions, or when visiting an outpatient clinic. 194 
The study used a paper-based self-report questionnaire. At enrolment, participants received a survey 195 
package including an information sheet, a consent form and the study instruments. The researcher also 196 
verbally explained the purpose and methods of the study face-to-face. 197 
3.7 The survey 198 
The survey comprised a number of validated questionnaires designed to gather data about 199 
medication adherence, patient beliefs, behavioural, attitudinal and other factors associated with 200 
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adherence/non-adherence. For Iraqi participants, all questionnaires were formally translated and 201 
validated in the Arabic language using best practice translation guidelines (Sousa & Rojjanasrirat, 202 
2011).  203 
Study instruments were translated into Arabic and then back-translated to English by two 204 
researchers independently (Epstein, Santo, & Guillemin, 2015). The researcher used the back-205 
translation method for achieving linguistic translations equivalent to the items in the source language 206 
(Duffy, 2006). Following the instrument translation recommendations, an expert translator translated 207 
the English versions of the questionnaires into Arabic. The Arabic translated version was then back-208 
translated to English by an independent expert with rich clinical experience in cardiology nursing, 209 
bilingual and fluent in both English and Arabic languages but unfamiliar with the study. The researcher 210 
then discussed and resolved minor rewording conflicts. All translations were conducted using clear, 211 
direct and simple phrases and questions suitable for older adults with low literacy levels. Content and 212 
face validity of the study questionnaires were assessed and confirmed by seven content experts with 213 
extensive experience in cardiac disease of various specialty backgrounds (cardiologist, senior 214 
pharmacists, cardiac nurse specialist and nursing educators). They reviewed the questionnaires using 215 
the Content Validity index, resulting in the wording of some items being slightly revised. The translated 216 
questionnaires were piloted with five cardiac patients from the three Iraqi hospitals; further minor 217 
modifications were made so the questionnaires could be easily understood. Sociodemographic and 218 
health data were collected, and completion took 10-15 minutes (Table 2). 219 
3.7.1 Medication adherence questionnaire 220 
The Medication Adherence Questionnaire (MAQ) scale (Morisky, Green, & Levine, 1986), is 221 
a short, self-reported measure designed to assess medication adherence behaviour and barriers such as 222 
forgetfulness, carelessness, adverse effects and efficacy. It contains four simple dichotomous questions 223 
(yes/no), scoring one point for each “yes” response and zero point for each “no” response. Scores are 224 
summed to derive a total score with higher numbers demonstrating greater medication non-adherence 225 
i.e. 0 =high to 3-4= low medication adherence behaviours. The validity and reliability of the MAQ was 226 
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originally established in patients with hypertension, with internal consistency of α = 0.61, sensitivity of 227 
0.81 and specificity of 0.44 (Lavsa, Holzworth, & Ansani, 2011). The MAQ score has been 228 
demonstrated to be a significant independent predictor of cardiovascular medication nonadherence by 229 
multivariate logistic regression (Shalansky, Levy, & Ignaszewski, 2004).  230 
3.7.2 The adherence to refills and medications scale 231 
The 12-item scale Adherence to Refills and Medications Scale (ARMS) (Kripalani et al., 2009) 232 
was used to determine medication adherence self-regulation. The ARMS consists of 12-items, the first 233 
8 items in the scale assessing the ability to self-administration for the prescribed medications and the 234 
last 4 items evaluating the patient’s ability to take medications on schedule. Each item is scored on a 235 
four-point scale ranging from l = none of the time to 4 = all the time. Scores are summed to derive a 236 
total score with higher numbers demonstrating better refill ability for medications on schedule. The 237 
ARMS and its subscales have been shown to correlate highly with other measures of medication 238 
adherence such as the four-item scale by Morisky and colleagues, and medication refill adherence 239 
(Mayberry, Gonzalez, Wallston, Kripalani, & Osborn, 2013). The ARMS has demonstrated high 240 
internal consistency among patients with low literacy skills (Kripalani et al., 2009).  241 
3.7.3 The belief about medicine questionnaire 242 
The short (eight-item) version of the Belief about Medicine Questionnaire (BaMQ) (Horne, 243 
Weinman, & Hankins, 1999) was used to evaluate patients’ beliefs about medications. The BaMQ 244 
identifies patients’ beliefs in the necessity of and concerns about their medicines. The BaMQ is 245 
composed of subscales (8 items) to assess specific necessity, specific concerns, general overuse and 246 
general harm. Each item is measured using a 5-point Likert scale range from l = strongly disagree to 5 247 
= strongly agree. Scores are summed to derive a total score with higher numbers demonstrating more 248 
positive beliefs. The internal consistency of the BMQ scale has been evaluated using Cronbach's alpha, 249 
showing inter-item correlation of General Harm= 0.44, p < 0.01); General Overuse= 0.64, p < 0.01); 250 
Specific Necessity= 0.79, p < 0.01); and Specific Concerns = 0.56, p < 0.01) (Schüz et al., 2011). The 251 
BaMQ has been shown to correlate significantly with other adherence-related scales such as the MAQ, 252 
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the Morisky Medication Adherence Scale (MMAQ), and medication adherence rating scale (MARS-5) 253 
(Mårdby, Åkerlind, & Jörgensen, 2007).    254 
3.7.4 The medication adherence self-efficacy scale-revised 255 
The 13-item Medication Adherence Self-Efficacy Scale-Revised (MASES-R) (Fernandez, 256 
Chaplin, Schoenthaler, & Ogedegbe, 2008) was used to evaluate an individual’s ability to adhere to 257 
their medication schedule under various challenging circumstances. The MASES-R consists of items 258 
that specifically examine patients’ confidence in taking medications in specific circumstances and their 259 
ability to take medications as part of everyday routine. Each item is measured using a 4-point Likert 260 
scale, ranging from 0 = not at all sure to 3 = extremely sure, with greater self-efficacy indicated by 261 
higher scores and a single score derived as the mean of all items. The MASES-R has been found 262 
correlate to significantly with electronic medication adherence records (MEMS) at 3-months, indicating 263 
support for the predictive validity of the MASES-R (Fernandez et al., 2008).  264 
3.7.5 Medication specific social support 265 
An eight-item Medication Specific Social Support (MSSS) scale (Lehavot et al., 2011) was 266 
used to identify how often patients receive assistance from others with their medication. Each item is 267 
measured using a 5-point Likert score for each item ranging from 0 = never to 4 = very often., with a 268 
high total mean of all items representing a high level of medication-specific support. 269 
3.8 Data analysis  270 
Data were checked and cleaned prior to entry into SPSS for Windows version 23. Descriptive 271 
statistics were used to analyse data related to the patients’ baseline characteristics in Australia and Iraq, 272 
level of medication adherence, medication adherence self-efficacy, beliefs about medication and social 273 
support. Optimal adherence was defined as having a score of greater than two on the four-item Morisky 274 
medication adherence scale. Bivariate analyses were conducted using the Spearman Correlation 275 
Coefficient to examine factors potentially associated with medication adherence. The levels of 276 
medication adherence were categorised as high and low/medium and compared between the 277 
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two patient groups by Chi-square (χ2) test. Variables significantly associated with medication 278 
adherence in bivariate analyses were examined by logistic regression, with significance set at P < 0.25 279 
in the preliminary bivariate analysis for entry into regression models and P < 0.05 for the regression 280 
analysis (Polit., 1996). Two sided tests were conducted and for all analyses, p values of <0.05 were 281 
considered statistically significant. 282 
4. Results 283 
4.1 Characteristics of participants 284 
Recruitment progressed at approximately 13 participants per month in a single general hospital 285 
in Australia and 20 participants per month at three specialised cardiac hospitals in Iraq. Between 286 
October 2016 and December 2017, in total 246 patients with CVD were recruited, n=120 in Australia, 287 
n=126 in Iraq, as: a) in-patients of a cardiac ward (n = 179) and b) out-patients attending cardiac 288 
rehabilitation in Australia and out-patient clinics in Iraq (n = 67).  289 
The characteristics of participants from Australia and Iraq are presented in Table 2. 290 
Sociodemographic, health and medication-related continuous data were provided by means and 291 
standard deviations, and categorical data by frequencies and percentages. Differences between 292 
patients from Australia and Iraq were tested using independent samples t-tests for continuous 293 
variables and Chi-square (χ2) test for categorical variables. Overall, Iraqi cardiac participants were 294 
significantly younger (t=9.82, p= 0.001) and more likely to be unemployed (chi2= 71.52, p=0.017), 295 
married or in a co-habiting relationship (chi2= 30.35, p=0.001). They were also significantly more likely 296 
to have a lower level of education (chi2= 26.49, p=0.001), comorbid disease (chi2= 10.90, p=0.001), 297 
and to take significantly more and different classes of cardiac medications per day than Australian 298 
cardiac participants (t= -5.71, p=0.001).  299 
4.2 Medication adherence 300 
Significantly more participants from Iraq reported medium/low levels of adherence to their 301 
cardiac medications compared to participants from Australia (64.3% versus 37.5%, respectively) and 302 
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fewer reported high levels of adherence to their cardiac medications than participants recruited in 303 
Australia (35.4% versus 62.5%); both p = 0.001 (Table 3). Significant associations were sought between 304 
socio-demographic and medication-related variables and medication adherence (Tables 4). In neither 305 
country were the sociodemographic or health variables significantly associated with medication 306 
adherence.  307 
The ARMS included 12-items measuring the ability to self-administer prescribed medications 308 
and evaluating the patient’s ability to take medications on schedule. Mean scores for the ability to self-309 
administer medications for the Australian participants (ranging from 23-40) and the Iraqi participants 310 
(ranging from 20-40) were 38.05 (SD=2.69) and 33.72 (SD=4.98), respectively (Table 5). Mean scores 311 
for the ability to refill medications on schedule (the last 4 items) for the Australian and Iraqi 312 
participants (ranging from 8 to 16) were 14.95 (SD=1.26) and 12.64 (SD=2.21), respectively. Mean 313 
scores for the ability to refill medication were highest in the Australian participants for the item “How 314 
often do you put off refilling your medicines because they cost too much money?” (mean= 3.94, SD= 315 
0.23) and in Iraqi participants for the item “How often do you decide not to take your medicine?” 316 
(mean= 3.59, SD= 0.68). Lowest reported mean scores for both Australian and Iraqi participants were 317 
for the item “How often do you plan ahead and refill your medicines before they run out?” (mean=3.43, 318 
SD= 0.9; mean=3.25, SD= 0.75, respectively) (Table 5). 319 
The BaMQ is composed of 8 items comprising subscales to assess specific necessity, specific 320 
concerns, general overuse and general harm. For Australian and Iraqi participants, mean scores for 321 
beliefs about the necessity of medications (ranging from 18 to 49 and 8 to 49, respectively) were 44.33 322 
(SD=6.14) and 34.57 (SD=11.05), respectively. Mean scores for concerns about medication were 5.05 323 
(SD=2.10) and 5.66 (SD=2.11), respectively. Mean scores about beliefs about the overuses of 324 
medication were 4.45 (SD=1.73) and 5.62 (SD=2.14), respectively. Mean scores about beliefs about 325 
the harms of medication were 4.13 (SD=1.45) and 4.88 (SD=2.24), respectively (Table 5). In this 326 
scale, most positive beliefs (highest scores) were reported for the item “My medicines protect me from 327 
becoming worse” (mean=4.6, SD=0.67; mean=4.25, SD=0.71 for Australian and Iraq participants, 328 
respectively). Lowest scores were reported for the item “People who take medicines should stop their 329 
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treatment for a while every now and again” (mean=1.83, SD=0.91) for Australian participants, but. 330 
the item “Medicines do more harm than good” had the lowest reported scores (mean=2.37, SD=1.19) 331 
amongst Iraqi participants.  332 
The medication adherence Self-Efficacy Scale-Revised consists of 13-items to assess patients’ 333 
confidence in taking medications and their ability to take medications as part of everyday routine. 334 
Mean MASES-R scores (ranging from 8 to 39) for Australian participants was 35.2 (SD= 5.78) and 335 
(ranging from 5 to 39) for the Iraqi participants was 27.1 (SD= 8.92) (Table 5). The highest score 336 
reported for the item “I feel confident to make taking my medicines part of my routine” for both 337 
Australian and Iraqi participants (mean= 2.84, SD= 0.43; mean= 2.33, SD= 0.85), respectively. For 338 
Australian participants, lowest scores were reported for the item “I feel confident taking my medicine 339 
when I worry about taking them for the rest of my life” (mean= 2.57, SD= 0.77); for Iraqi participants, 340 
the item “I feel confident taking my medicine when I feel well” (mean= 1.90, SD= 1.07) was scored 341 
lowest. 342 
Mean scores for the Medication Specific Social Support scale (ranging from 0 to 32) for the 343 
Australian sample were 11.42 (SD= 7.02) and (ranging from 0 to 40) for the Iraqi sample was 10.57 344 
(SD= 9.13) (Table 5). The highest scored item by the Australian group was “How often has someone 345 
in the past helped you understand information about your medicines?” (mean= 1.86, SD= 1.19), but 346 
for the item “How often has someone in the past picked up your cardiac medicines prescriptions for 347 
you?” in the Iraqi group (mean= 2.69, SD= 1.3). The lowest scored item was “How often has someone 348 
in the past called you specifically to ask how you were doing with your cardiac medicines?” for both 349 
Australian and Iraqi participants (mean= 0.87, SD= 1.24; mean= 1.61, SD= 1.69, respectively).  350 
Binary logistic regression analysis was used to assess the predictors of medication adherence 351 
examining the samples from both countries together and separately. After adjusting for confounding 352 
factors, five potential predictors including age, location of recruitment (cardiac ward versus cardiac 353 
rehabilitation or outpatient clinic), ability to correctly self-administer and refill medications, medication 354 
adherence self-efficacy and beliefs about medication were included in the models. For the combined 355 
sample, country of origin was also added (Table 6) but was not found to exert significant effect. In all 356 
the models, patients’ ability to correctly self-administer and refill their medications was significantly 357 
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predictive of their reported adherence behaviours (Tables 6, 7a, 7b). In the Australian model (Table 7a), 358 
beliefs about medications made a small additional significant contribution (odds ratio= 1.142, 95% CI: 359 
1.005-1.298, p= 0.041). In the Iraqi sample (Table 5b), beliefs about medications (odds ratio= 1.224, 360 
95% CI: 1.090-1.375, p= 0.001) as well as location of recruitment (cardiac ward versus cardiac clinics) 361 
were also significantly predictive, with patients recruited from an out-patient cardiac clinic significantly 362 
more likely to report adherence that patients recruited in a cardiac ward (odds ratio= 0.300, 95% CI: 363 
0.093-0.966, p= 0.044) (Table 7b). 364 
All the models recorded significant Omnibus tests (p < 0.001). In the combined sample model, 365 
the Pseudo R Square statistic indicated that the model as whole explained 39.4% (Cox and Snell R 366 
Square =0.394) and 52.5% (Nagelkerke R Square = 0.525) of the variance in cardiac medications 367 
adherence. ARMS + BaMQ explained 39.6% of variance but ARMS alone explained 36.6% of variance 368 
in MAQ. In the separate Australian and Iraqi samples, the Pseudo R Square statistic indicated that the 369 
models as whole explained between 38.7% versus 42.6% (Cox and Snell R Square =0.387 versus 0.426) 370 
and 52.8% versus 58.5% (Nagelkerke R Square = 0.528 versus 0.585, respectively) of the variance in 371 
cardiac medications adherence, respectively.  372 
5. Discussion 373 
To our knowledge, this is the first study to report and compare adherence to cardiac medications 374 
and associated factors in patients with CVD in Australia and Iraq. Based on our findings, self-reported 375 
adherence to cardiac medications in both Australian and Iraqi patients with CVD was far from optimal. 376 
Adherence to cardiac medications was suboptimal in Australian patients, with 37.5% not achieving 377 
reasonable levels; similar problems have also been reported in cross-sectional survey of patients with 378 
chronic disease in Australia (Laba, Lehnbom, Brien, & Jan, 2015). In developed countries, long-term 379 
medication adherence for chronic diseases has been reported to range from 30%-70% of treated patients 380 
(Degli Esposti et al., 2012). Non-adherence has been reported by 39% of Italian patients with ischaemic 381 
stroke (Colivicchi, Bassi, Santini, & Caltagirone, 2007) and by 38.3% of Canadian patients with heart 382 
failure (George & Shalansky, 2007). The results of a meta-analysis indicated unsatisfactory long-term 383 
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cardiac medication adherence in Australian patients with CVD, with prevalence rates of medication 384 
non-adherence ranging between 14% and 43% in 2010 to 2014 (McKenzie et al., 2015). 385 
Compared to developed countries, in developing countries medication adherence rates have 386 
been generally reported as lower (Ma, 2016), reflected in our findings where Australian patients were 387 
significantly more likely to have high adherence compared to patients from Iraq. These findings align 388 
with other studies from other developing countries: non-adherence was reported by 41.5% of patients 389 
with hypertension in southwest Nigeria (Osamor & Owumi, 2011) and 51.5% of patients with CVD in 390 
Kyrgyzstan (Murphy, Jakab, McKee, & Richardson, 2016). Similarly, 54.2% of Palestinian patients 391 
with hypertension (Al-Ramahi, 2015) and 58.1% of Malaysian patients with CVD (Khonsari et al., 392 
2015) were non-adherent. Our study showed suboptimal adherence levels for a significant proportion 393 
of the cohorts in both countries, indicating the need for urgent attention. Study findings demonstrated 394 
significant differences in sociodemographic characteristics between Australian and Iraqi samples. 395 
However, none of the sociodemographic characteristics were found to be statistically associated with 396 
medication adherence. In comparing the two countries, major differences in socioeconomic 397 
development and health disparities may be reflected between the two groups as developed and 398 
developing countries. The healthcare system in Iraq, including cardiac disease management, is in early 399 
stages of development, which may relate to the low rates of adherence to cardiac medications seen in 400 
this study. The cultural implications and perceptions about taking medications may differ between 401 
developed and developing countries in terms of knowledge, attitudes and beliefs, and these may 402 
underpin medication adherence behaviours, especially for ethnic minority groups (Alzubaidi, 403 
McMamara, Chapman, Stevenson, & Marriott, 2015). Likewise, cultural differences in the 404 
understanding of chronic disease and the role of therapy, healthcare attendance, and the interactions 405 
between patients and healthcare professionals in developed and developing countries may profoundly 406 
influence the prevalence of medication adherence (Bowry et al., 2011). Further studies are required to 407 
add detail to the patterns of non-adherence in relation to specific cardiac medications in Australia and 408 
Iraq, and then to promote interventions in frontline cardiac care settings, testing their ability to enhance 409 
adherence to medications and to have significant impact on morbidity and mortality rates. 410 
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5.1 Factors associated with medication adherence  411 
There is currently limited knowledge of factors associated with medication non-adherence in 412 
patients with CVD, with little work exploring knowledge, attitudes, beliefs and related behaviours 413 
(Crowley et al., 2015). In both Australia and Iraq, analysed as a combined sample or individually for 414 
each country, the ability to correctly self-administer and refill medications significantly (p<0.001) 415 
predicted adherence behaviours. This suggests major behavioural drivers may be similar across 416 
countries despite cultural differences. These findings are consistent with the results of previous studies 417 
with other patient groups, such as Swiss patients with hypertension (Zeller, Taegtmeyer, Martina, 418 
Battegay, & Tschudi, 2008), American patients on warfarin therapy (Orensky & Holdford, 2005) and 419 
patients with CVD in Canada (Reidel, Tamblyn, Patel, & Huang, 2008), where the ability to refill 420 
medication independently predicted adherence behaviour but with the association declining with 421 
increasing regimen complexity. 422 
The elements of the TPB conform to and define the ability to refill cardiac medication and 423 
beliefs about medication as attitudes and behaviours that predict greater medication adherence and 424 
mediate the relationship between treatment and medication adherence. Poorer ability to self-administer 425 
and refill medications can be due to poor patient knowledge about treatments, particularly in older 426 
patients (Ratanawongsa et al., 2013); to cognitive dysfunction (Platt et al., 2008), low social support 427 
(Park et al., 2015) and lower economic status (World Health Organisation, 2003). Healthcare 428 
professionals should ensure that all patients have adequate knowledge, skills and understanding in self-429 
administration of their medications. This is particularly important in older populations, as these skills 430 
may tend to decline with age and increase with forgetfulness.  431 
In addition, in the current study, beliefs about medication were a significant predictor of cardiac 432 
medication adherence: findings that provide further support to the Theory of Planned Behaviour. 433 
According to this theory, individuals’ beliefs are strong predictors of their intentions and possibly of 434 
actual health behaviours such as medication adherence (Ajzen, 1991). This study findings are in line 435 
with the TPB proposition that medication adherence intention can be influenced by patient attitudes 436 
toward adherence behaviour, which can be determined by their beliefs about the necessity of performing 437 
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this behaviour (Redding, Rossi, Rossi, Velicer, & Prochaska, 2000). The behavioural intention of 438 
medication adherence might also be influenced by factors which may be beyond an individual’s control, 439 
including ability to refill medications and their psychosocial and health characteristics.  440 
These findings are congruent with those of Ruppar, Dobbels, and De Geest (2012) who found 441 
that stronger belief in the necessity of antihypertensive medications could predict better adherence 442 
among American patients (OR= 2.027, P = 0.024; CI: 1.097-3.645). Similarly, in patients with negative 443 
beliefs about the necessity of their medications, non-adherence rates were double that of those with less 444 
negative beliefs (Gatti, Jacobson, Gazmararian, Schmotzer, & Kripalani, 2009). These patients were 445 
more likely to intentionally skip doses and report forgetfulness (World Health Organisation, 2003). 446 
Similar findings have been reported in studies conducted in Oman, where stronger beliefs about the 447 
necessity of hypertensive medications were significant predictors of medication adherence (Al-448 
Noumani et al., 2017).  449 
Studies have suggested that patients’ ability to self-administer and refill medications and their 450 
beliefs about medications may be affected by their level of education (Park et al., 2015), the number of 451 
prescribed medications (Karakurt & Kaşikçi, 2012) and comorbid conditions (Molloy & O’Carroll, 452 
2017). Given the differing national contexts and variation in the sociodemographic characteristics 453 
between the Australian and Iraqi groups, differential effects might have been anticipated. However, no 454 
sociodemographic or health related factors retained significance in multivariate modelling to predict 455 
medication adherence. The similarity of the findings from the two countries are striking; despite their 456 
very different cultures, independently predictive variables showed little difference. Further research is 457 
required to fully understand the perceived barriers to refilling medication, detail of beliefs and 458 
confidence to take medication.   459 
Study findings indicated that the location of recruitment in relation to CVD services (cardiac 460 
ward versus cardiac clinics, a proxy for differing time points in the cardiac patient journey) was a 461 
significant predictor of medication adherence among Iraqi patients, with more participants from the 462 
cardiac ward having medium/low adherence than those recruited as out-patients. It might have been 463 
anticipated that patients admitted for an acute cardiac event might report worse medication adherence 464 
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than patients seen as out-patients, who might reasonably be expected to be more clinically stable. 465 
However, this pattern was not seen in patients recruited in Australia. No research has previously 466 
examined the relationship between cardio-protective medication adherence and service provider 467 
location/cardiac patient journey time point in Iraq, where poor adherence with cardiovascular 468 
medications might be attributed to CVD service deficiencies both for in-patients and out-patients 469 
(Kronish & Ye, 2013). Another possible explanation might be that patients’ opportunities to attend 470 
cardiac clinics were less in Iraq, with those attending being generally more motivated, perseverant, and 471 
willing to attend follow-up with their cardiologists, with consequently relatively better medication 472 
adherence (Bedell et al., 2000). Perhaps more medication education was delivered in the out-patient 473 
clinics than in the cardiac wards in Iraq, but with less variation in Australia. The study findings highlight 474 
the importance of patient education and medication related knowledge to enhance adherence behaviour 475 
in cardiac ward before patient discharge, in out-patient clinics and cardiac rehabilitation settings (Curl 476 
et al., 2016). Iraqi patients with CVD might have experienced particular problems in accessing quality 477 
health services due to the lack of or limited resources which might include provision of medications in 478 
public hospitals. This study reveals the need for nursing educational interventions to not only educate 479 
patients on their medications and send out reminders but also address patients’ beliefs about their 480 
medications and their ability to self-administer and refill medications. 481 
5.2 Limitations of the study 482 
This study is attended by a number of limitations. Although medication adherence self-reports 483 
are useful and have been shown to be reasonably accurate measures of medication adherence, this 484 
approach can be susceptible to information and social desirability bias (Morisky & DiMatteo, 2011). 485 
Further, our adherence measure did not distinguish between specific cardiac medication classes but 486 
rather medication adherence behaviour generally (Crowley et al., 2015). For many of those tools, 487 
particularly the MAQ, there are to date only limited validation and reliability data available, 488 
which may limit confidence in their ability to accurately indicate patients’ adherence to their 489 
medications. Cardiac patients’ beliefs about medication and their ability to refill cardiac medication 490 
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may have been influenced by the type of cardiac medications taken by study participants due to 491 
differences in side effects and cost. The differences in sociodemographic characteristics and some 492 
health-related variables between Australian and Iraqi samples may limit the interpretation of the 493 
comparative findings. Future research should include and recognise different classes of cardiac 494 
medications. Data were collected utilising convenience sampling from three different hospitals in Iraq 495 
and one hospital from Australia. Convenience sampling from multiple sites may have allowed the 496 
sample to better represent these populations with regard to demographic characteristics. Finally, longer-497 
term follow-up would add valuable information about the sustainability of medication adherence 498 
behaviours across the cardiac patient journey.      499 
6. Conclusion  500 
The findings of this cross-sectional study are unique in terms of comparing cardiac medication 501 
adherence behaviours between patients from developed and developing countries: Australia and Iraq. 502 
The study results sought to inform new behavioural nurse-led approaches to improve medication 503 
adherence in patients with CVD. For the future such behavioural interventions should include ability to 504 
refill medications and address medication-related beliefs to encourage medication adherence. Further 505 
follow up study is needed in both Australia and Iraq, where strategies should be tailored to target these 506 
factors that have been shown to predict patients’ adherence behaviours across cultures and 507 
settings/disease time points. New interventions are urgently required to improve the unacceptably poor 508 
medication adherence in both Australia and Iraq. 509 
The findings of this study have crucial implications for nursing practice, education, policy and 510 
future research. Findings indicate that nurses should focus on exploring patients’ beliefs about their 511 
medications and promote accurate knowledge of cardiac medications. This should also include a focus 512 
on ability self-administer and refill medications, taking into account individual and local situations and 513 
contexts, including, for example, the geo-political situation of the Middle East. Nurse can use study 514 
findings to inform development and implementation of nurse-led interventions to enhance cardio-515 
protective medication adherence in Australia and Iraq, with clinical and cost-effectiveness outcomes 516 
informing clinical practice. Such interventions should address the principal behavioural causes of sub-517 
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optimal adherence especially patients’ belief about medication and their ability to correctly self-518 
administer and refill medications. They should enable nurses to strengthen patients’ knowledge and 519 
beliefs through motivational consultations, education and information sessions. Future research is 520 
recommended to explore predictors of medication adherence in greater depth and in broader CVD 521 
populations in both Australia and Iraq. Nurse-led interventions developed to apply study findings should 522 
be the subject of future trials in Australia and Iraq. The information provided by this study can support 523 
development of behaviour change interventions delivered by nurses across a wide range of cultures and 524 
settings and time points in the CVD journey. 525 
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